Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

British Journal of Cancer

Volumn 115, Issue 11, 2016, Pages 1313-1320

  Ledermann, Jonathan A ^a   Harter, Philipp ^b   Gourley, Charlie ^c   Friedlander, Michael ^d   Vergote, Ignace ^e   Rustin, Gordon ^f   Scott, Clare ^g   Meier, Werner ^h   Shapira Frommer, Ronnie ⁱ   Safra, Tamar ^j   Matei, Daniela ^k   Fielding, Anitra ^l   Bennett, Bryan ^l,n   Parry, David ^l   Spencer, Stuart ^l   Mann, Helen ^l   Matulonis, Ursula ^m  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KLINIKEN ESSEN MITTE   (Germany)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f MOUNT VERNON HOSPITAL   (United Kingdom)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h Children s Hospital   (Germany)

ⁱ SHEBA MEDICAL CENTER   (Israel)

^j TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^k INDIANA UNIVERSITY   (United States)

^l ASTRAZENECA   (United Kingdom)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ ADELPHI REAL WORLD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OLAPARIB; ANTINEOPLASTIC AGENT; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PLACEBO;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; DRUG EFFECT; DRUG SENSITIVITY; FATIGUE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA AND VOMITING; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION; AGED; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; PLACEBOS; QUALITY OF LIFE; YOUNG ADULT;

EID: 84994614085     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.348     Document Type: Article

References (16)

1. AstraZeneca (2015) Global Policy: Bioethics. Available at https:// www.astrazeneca.com/sustainability/responsible-research.html.
2. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251.
3. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309: 814-822.
4. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11: 570-579.
5. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J (2008) Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 14: 3916-3925.
6. Friedlander ML, King MT (2013) Patient-reported outcomes in ovarian cancer clinical trials. Ann Oncol 24(Suppl 10): x64-x68.
7. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, MacPherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852-861.
8. Gridelli C, De Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Corral J, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouaki N, Visseren-Grul C, Paz-Ares LG (2012) Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 7: 1713-1721.
9. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira Frommer R, Safra T, Matei D, MacPherson E, Watkins C, Carmichael J, Matulonis U (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366: 1382-1392.
10. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15: 852-861.
11. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J (2005) Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41: 280-287.
12. Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh dY, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Woo SY, Jung SH, Ahn JS, Im YH (2015) Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Res Treat 152: 77-85.
13. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ,Martin NM, Borst P, Jonkers J (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105: 17079-17084.
14. Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, OlsenMR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P (2015) Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexedbevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous nonsmall-cell lung cancer. J Thorac Oncol 10: 353-359.
15. Stockler MR, Hilpert F, Friedlander M, KingMT, Wenzel L, Lee CK, Joly F, de GN, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E (2014) Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinumresistant ovarian cancer. J Clin Oncol 32: 1309-1316.
16. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244.